Compare NWTG & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWTG | GNPX |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 6.4M |
| IPO Year | N/A | 2017 |
| Metric | NWTG | GNPX |
|---|---|---|
| Price | $1.60 | $1.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 20.9K | ★ 824.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 76.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $128.27 | N/A |
| Revenue Next Year | $70.26 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.82 | $0.14 |
| 52 Week High | $3.50 | $12.97 |
| Indicator | NWTG | GNPX |
|---|---|---|
| Relative Strength Index (RSI) | 54.31 | 43.68 |
| Support Level | $1.51 | $1.90 |
| Resistance Level | $1.79 | $2.51 |
| Average True Range (ATR) | 0.10 | 0.20 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 67.27 | 12.54 |
Newton Golf Co Inc is a technology-forward golf company dedicated to revolutionizing the sport with cutting-edge, high-performance products. The company's expanding portfolio includes golf shafts, putters, grips, and other golf-related accessories designed for golfers of all skill levels. The company sells its products through e-commerce, distributors, wholesale customers, including pro-shops at golf courses and off-course retailers, sporting goods retailers, online retailers, third-party distributors, and through Club Champion Golf, as well as through mass merchants and corporate customers in the Americas, Asia, and Europe.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.